Pietragallo Gordon Alfano Bosick & Raspanti LLP

Pennsylvania

General

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Cases51

Challenger50%

Patent Owner50%

NPE50%

pietragallo-gordon

pietragallo.com

Practice Areas

Transport., E-Comm.BiotechMech Eng, Manuf

Top Attorneys

Patrick J. CoyneNeal S. CohenPeter Kinsella

Elite Ratings

DCTPTABCAFC

Ratings

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Experience

Grade

Trend

DCT

PTAB

CAFC

Analytics

Lawyers

Cases

Ratings Trends

Practice Areas

Recent Dockets

Entered	Case	Description
09/13/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024) CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024)
08/13/24	Moskowitz Family LLC v. Globus Medical Inc 2:20-CV-03271 ( E.D. PA )	ORDER THAT PLAINTIFF'S MOTION FOR COSTS PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 54 (d) IS DENIED WITHOUT PREJUDICE. PLAINTIFF'S MOTION FOR ATTORNEYS FEES UNDER 35 U.S.C. & 285 IS DENIED; ETC.. SIGNED BY CHIEF JUDGE MITCHELL S. GOLDBERG ON 8/13/24. 8/13/24 ENTERED AND E-MAILED.(JL) (Entered: 08/13/2024)
08/13/24	Moskowitz Family LLC v. Globus Medical Inc 2:20-CV-03271 ( E.D. PA )	MEMORANDUM OPINION; ETC.. SIGNED BY CHIEF JUDGE MITCHELL S. GOLDBERG ON 8/13/24. 8/13/24 ENTERED AND E-MAILED.(JL) (Entered: 08/13/2024)
08/13/24	Moskowitz Family LLC v. Globus Medical Inc 2:20-CV-03271 ( E.D. PA )	PLAINTIFF MOSKOWITZ FAMILY LLCS REPLY MEMORANDUM IN SUPPORTOF ITS MOTION FOR JUDGMENT AS A MATTER OF LAW UNDER RULE 50(b)AND/OR FOR A NEW TRIAL UNDER RULE 59. (JL) (Entered: 08/13/2024)
08/13/24	Moskowitz Family LLC v. Globus Medical Inc 2:20-CV-03271 ( E.D. PA )	ORDER THAT PLAINTIFF'S MOTION FOR LEAVE TO FILE A REPLY BRIEF IS GRANTED. PLAINTIFF'S MOTION FOR JUDGMENT AS A MATTER OF LAW UNDER RULE 50 (a) AND/OR FOR A NEW TRIAL UNDER RULE 59 IS DENIED; ETC.. SIGNED BY CHIEF JUDGE MITCHELL S. GOLDBERG ON 8/13/24. 8/13/24 ENTERED AND E-MAILED.(JL) (Entered: 08/13/2024)
08/13/24	Moskowitz Family LLC v. Globus Medical Inc 2:20-CV-03271 ( E.D. PA )	MEMORANDUM OPINION; ETC.. SIGNED BY CHIEF JUDGE MITCHELL S. GOLDBERG ON 8/13/24. 8/13/24 ENTERED AND E-MAILED.(JL) (Entered: 08/13/2024)
06/18/24	Theravance Biopharma R&D IP LLC v. Qui Pharmaceutical Co Ltd 2:24-CV-02689 ( E.D. PA )	Disclosure Statement Form pursuant to FRCP 7.1 by MYLAN IRELAND LIMITED, Mylan Specialty L.P., THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA R&D IP, LLC, THERAVANCE BIOPHARMA US, INC..(SOLLER, ERIC) (Entered: 06/18/2024)
06/18/24	Theravance Biopharma R&D IP LLC v. Qui Pharmaceutical Co Ltd 2:24-CV-02689 ( E.D. PA )	Disclosure Statement Form pursuant to FRCP 7.1 by MYLAN IRELAND LIMITED, Mylan Specialty L.P., THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA R&D IP, LLC, THERAVANCE BIOPHARMA US, INC..(SOLLER, ERIC) (Entered: 06/18/2024)
06/18/24	Theravance Biopharma R&D IP LLC v. Qui Pharmaceutical Co Ltd 2:24-CV-02689 ( E.D. PA )	COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-17547918.), filed by THERAVANCE BIOPHARMA R&D IP, LLC, MYLAN IRELAND LIMITED, THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA US, INC., Mylan Specialty L.P.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Civil Cover Sheet, # 10 Designation Form)(SOLLER, ERIC) (Entered: 06/18/2024) COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-17547918.), filed by THERAVANCE BIOPHARMA R&D IP, LLC, MYLAN IRELAND LIMITED, THERAVANCE BIOPHARMA IRELAND LIMITED, THERAVANCE BIOPHARMA US, INC., Mylan Specialty L.P.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Civil Cover Sheet, # 10 Designation Form)(SOLLER, ERIC) (Entered: 06/18/2024)
01/05/23	Lambeth Magnetic Structures LLC v. Seagate Technology US Holdings Inc 2:16-CV-00538 ( W.D. PA )	USCA Case Number 2023-1335 for 532 Notice of Appeal, filed by LAMBETH MAGNETIC STRUCTURES, LLC. USCA for the Federal Circuit Deputy Clerk M. Ames (DOCUMENT IS RESTRICTED AND CAN ONLY BE VIEWED BY COURT STAFF) (ctb) (Entered: 01/05/2023)